Predictive factors of lamivudine treatment success in a hepatitis B virus-infected pediatric cohort: A 10-year study

Canadian Journal of Gastroenterology

Volumn 26, Issue 7, 2012, Pages 429-435

  Yousef, Yasmine ^a   Béland, Kathie ^a   Mas, Emmanuel ^b   Lapierre, Pascal ^a   Bouron Dal Soglio, Dorothée ^a   Alvarez, Fernando ^a,c  

^a UNIVERSITY OF MONTREAL   (Canada)

^b HÔPITAL DES ENFANTS   (France)

^c UNIVERSITÉ DE MONTRÉAL   (Canada)

Author keywords

Hepatitis B; Lamivudine; Pediatric; Predictive success factors

Indexed keywords

ALANINE AMINOTRANSFERASE; HEPATITIS B(E) ANTIGEN; LAMIVUDINE; VIRUS DNA;

ABSENCE OF SIDE EFFECTS; ADOLESCENT; ADULT; ARTICLE; CANADA; CHILD; COHORT ANALYSIS; FEMALE; GENOTYPE; HEPATITIS B; HEPATITIS B VIRUS; HUMAN; MALE; PREDICTIVE VALUE; PRESCHOOL CHILD; PRIORITY JOURNAL; RISK FACTOR; SCHOOL CHILD; TREATMENT OUTCOME; TREATMENT RESISTANT DEPRESSION; VIRUS MUTANT;

EID: 84863747554     PISSN: 08357900     EISSN: None     Source Type: Journal    
DOI: 10.1155/2012/928912     Document Type: Article

References (33)

1. Sorrell MF, Belongia EA, Costa J, et al. National Institutes of Health consensus development conference statement: Management of hepatitis B. Hepatology 2009;49:S4-S12.
2. Marotta P, Lucas K. Management of hepatitis B: A longitudinal national survey - impact of the Canadian Hepatitis B Consensus Guidelines. Can J Gastroenterol 2010;24:537-42.
3. Hoofnagle JH, di Bisceglie AM. The treatment of chronic viral hepatitis. N Engl J Med 1997;336:347-56.
4. Feld JJ, Wong DK, Heathcote EJ. Endpoints of therapy in chronic hepatitis B. Hepatology 2009;49:S96-S102.
5. Chang MH. Natural history and clinical management of chronic hepatitis B virus infection in children. Hepatol Int 2008;2:28-36.
6. Sokal EM, Conjeevaram HS, Roberts EA, et al. Interferon alfa therapy for chronic hepatitis B in children: A multinational randomized controlled trial. Gastroenterology 1998;114:988-95. (Pubitemid 28217565)
7. Sokal EM, Kelly DA, Mizerski J, et al. Long-term lamivudine therapy for children with HBeAg-positive chronic hepatitis B. Hepatology 2006;43:225-32.
8. Yuen MF, Fong DY, Wong DK, et al. Hepatitis B virus DNA levels at week 4 of lamivudine treatment predict the 5-year ideal response. Hepatology 2007;46:1695-703.
9. Chang TT, Lai CL, Chien RN, et al. Four years of lamivudine treatment in Chinese patients with chronic hepatitis B. J Gastroenterol Hepatol 2004;19:1276-82.
10. Bortolotti F, Guido M, Bartolacci S, et al. Chronic hepatitis B in children after e antigen seroclearance: Final report of a 29-year longitudinal study. Hepatology 2006;43:556-562.
11. Bortolotti F, Cadrobbi P, Crivellaro C, et al. Long-term outcome of chronic type B hepatitis in patients who acquire hepatitis B virus infection in childhood. Gastroenterology 1990;99:805-10. (Pubitemid 20243374)
12. Iorio R, Giannattasio A, Cirillo F, D'Alessandro L, Vegnente A. Long-term outcome in children with chronic hepatitis B: A 24-year observation period. Clin Infect Dis 2007;45:943-9. (Pubitemid 47580340)
13. Hagmann S, Chung M, Rochford G, et al. Response to lamivudine treatment in children with chronic hepatitis B virus infection. Clin Infect Dis 2003;37:1434-40. (Pubitemid 37494669)
14. Hom X, Little NR, Gardner SD, Jonas MM. Predictors of virologic response to lamivudine treatment in children with chronic hepatitis B infection. Pediatr Infect Dis J 2004;23:441-5. (Pubitemid 38621483)
15. Jonas MM, Mizerski J, Badia IB, et al. Clinical trial of lamivudine in children with chronic hepatitis B. N Engl J Med 2002;346:1706-13. (Pubitemid 34547484)
16. Jonas MM, Little NR, Gardner SD. Long-term lamivudine treatment of children with chronic hepatitis B: Durability of therapeutic responses and safety. J Viral Hepat 2008;15:20-27. (Pubitemid 350243578)
17. Ni YH, Huang FC, Wu TC, et al. Lamivudine treatment in maternally transmitted chronic hepatitis B virus infection patients. Pediatr Int 2005;47:372-7.
18. Bedossa P, Poynard T. An algorithm for the grading of activity in chronic hepatitis C. The METAVIR Cooperative Study Group. Hepatology 1996;24:289-93. (Pubitemid 26260021)
19. Costa J, Lopez-Labrador FX, Sanchez-Tapias JM, et al. Microwave treatment of serum facilitates detection of hepatitis B virus DNA by the polymerase chain reaction. Results of a study in anti-HBe positive chronic hepatitis B. J Hepatol 1995;22:35-42.
20. Lindh M, Andersson AS, Gusdal A. Genotypes, nt 1858 variants, and geographic origin of hepatitis B virus - large-scale analysis using a new genotyping method. J Infect Dis 1997;175:1285-93. (Pubitemid 27225029)
21. Marx G, Martin SR, Chicoine JF, Alvarez F. Long-term follow-up of chronic hepatitis B virus infection in children of different ethnic origins. J Infect Dis 2002;186:295-301. (Pubitemid 34816312)
22. Evans AA, Fine M, London WT. Spontaneous seroconversion in hepatitis B e antigen-positive chronic hepatitis B: Implications for interferon therapy. J Infect Dis 1997;176:845-50. (Pubitemid 27411024)
23. Zoulim F, Poynard T, Degos F, et al. A prospective study of the evolution of lamivudine resistance mutations in patients with chronic hepatitis B treated with lamivudine. J Viral Hepat 2006;13:278-88.
24. Liaw YF, Chien RN, Yeh CT. No benefit to continue lamivudine therapy after emergence of YMDD mutations. Antivir Ther 2004;9:257-62.
25. Shin JW, Chung YH, Choi MH, et al. Precore stop codon mutation of hepatitis B virus is associated with low breakthrough rate following long-term lamivudine therapy. J Gastroenterol Hepatol 2005;20:844-9. (Pubitemid 40897164)
26. Cho SW, Hahm KB, Kim JH. Reversion from precore/core promoter mutants to wild-type hepatitis B virus during the course of lamivudine therapy. Hepatology 2000;32:1163-9.
27. Reijnders JG, Perquin MJ, Zhang N, Hansen BE, Janssen HL. Nucleos(t)ide analogues only induce temporary hepatitis B e antigen seroconversion in most patients with chronic hepatitis B. Gastroenterology;139:491-8.
28. Kobak GE, MacKenzie T, Sokol RJ, Narkewicz MR. Interferon treatment for chronic hepatitis B: Enhanced response in children 5 years old or younger. J Pediatr 2004;145:340-5. (Pubitemid 39165682)
29. Yeung LT, Ling SPC, Ng VL, O'Conor C, Roberts EA. Achieving inactive carrier status in childhood hepatitis B virus infection: 25 years' experience. Hepatology 2010;54:1027A.
30. Choe BH, Lee JH, Jang YC, et al. Long-term therapeutic efficacy of lamivudine compared with interferon-alpha in children with chronic hepatitis B: The younger the better. J Pediatr Gastroenterol Nutr 2007;44:92-8. (Pubitemid 46071799)
31. Dienstag JL. Benefits and risks of nucleoside analog therapy for hepatitis B. Hepatology 2009;49:S112-21.
32. Hartman C, Berkowitz D, Shouval D, et al. Lamivudine treatment for chronic hepatitis B infection in children unresponsive to interferon. Pediatr Infect Dis J 2003;22:224-9.
33. Chan HL, Wong VW, Wong GL, et al. Early hepatitis B virus DNA suppression can predict virologic response to peginterferon and lamivudine treatment. Clin Gastroenterol Hepatol 2008;6:1022-6.